Startup profile · funding coverage
Encoded Therapeutics funding, valuation and investors
Clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders.
Keep track of Encoded Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series F
$275M · September 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$275M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · South San Francisco, California, USA
Investors in latest funding
Lead: GV , Undisclosed healthcare fund
Other: ARCH Venture Partners , RTW Investments
Overview
Encoded Therapeutics develops one-time precision genetic medicines using a vector-engineering platform designed for targeted, cell-type-selective control of gene expression in the brain and peripheral nervous system. Its lead program, ETX101, targets SCN1A+ Dravet syndrome.
Why Encoded Therapeutics is interesting
Its $275M Series F funds ETX101 pivotal development in Dravet syndrome, internal GMP scale-up, and a broader neurology pipeline.
Product & use cases
Precision genetic medicines for monogenic and common neurological disorders, supported by internal discovery, development, and GMP manufacturing capabilities.
- One-time genetic medicine for SCN1A+ Dravet syndrome
- Precision genetic medicines for neurological disease
- Internal GMP manufacturing for clinical and commercial scale-up
Key facts
- $275M Series F closed Sep 9, 2026, co-led by GV and an unnamed healthcare fund
- ETX101 pivotal and expansion studies in Dravet syndrome
- ETX301 targeted for a 2027 IND submission
Funding history (newest first)
Series F
2026-09 $275M- GV (lead)
- Undisclosed healthcare fund (lead)
- ARCH Venture Partners (participant)
- RTW Investments (participant)
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Encoded Therapeutics's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.